Skip to main content
. Author manuscript; available in PMC: 2010 Mar 11.
Published in final edited form as: J Neurophysiol. 2007 Dec 26;99(3):1515–1522. doi: 10.1152/jn.00598.2007

FIG. 5.

FIG. 5

ABT-737 delays decline in synaptic potentials after injection of 20 µg/ml recombinant ΔN BCL-xL into the presynaptic terminal. A: examples of change in slope of postsynaptic potentials over time after injection of ΔN BCL-xL or ΔN BCL-xL/ABT-737 solution. B: combined data comparing the half time of rundown of synaptic function in ΔN BCL-xL-injected synapses vs. synapses injected with ΔN BCL-xL + ABT-737 (n = 3 for ΔN BCL-xL alone and n = 5 for ΔN BCL-xL/ABT-737.

HHS Vulnerability Disclosure